Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + Paclitaxel Polymeric Micelles in Recurrent/Refractory SCLC
NCT07819591Phase 2Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab and Paclitaxel Micelles for Injection in small cell lung cancer (SCLC). Primary endpoint: Objective Response Rate up to 36 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ivonescimabPaclitaxel Micelles for Injection
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07819591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07819591.